Lipid emulsions of palmitoylrhizoxin: effects of composition on lipolysis and biodistribution.
Four types of lipid emulsion for highly lipophilic antitumour agent RS-1541 (13-O-palmitoylrhizoxin) with mean particle diameters of 200-260 nm were prepared using soybean oil (SOY) or dioctanoyldecanoylglycerol (ODO) for the oil phase and lecithin (LEC) or polyoxyethylene-(60)-hydrogenated castor oil (HCO-60) for surfactants. The lipolysis rate of HCO-60-emulsified emulsions by lipoprotein lipase was much slower than that of LEC-emulsified emulsions. Particle sizes of emulsions incubated in plasma with the lipase for six hours were 75%, 79%, 101%, and 93% of initial values for SOY/LEC, ODO/LEC, SOY/HCO-60, and ODO/HCO-60 emulsions, respectively, showing an apparent size decrease for LEC-emulsified emulsions. In rats, uptake clearance values of SOY/LEC and ODO/LEC emulsions of RS-1541 in the reticuloendothelial system (RES) were 81.2 and 135.3 mL h(-1), respectively, and AUC values were 4.0 and 1.3 microg h mL(-1), respectively. In contrast, RES uptake clearances of HCO-60 emulsions of RS-1541 were considerably lower (4.2 mL h(-1) for SOY/HCO-60; 2.2 mL h(-1) for ODO/HCO-60), resulting in high AUC values (35.4 microg h mL(-1) for SOY/ HCO-60; 63.9 microg h mL(-1) for ODO/HCO-60). The concentrations of RS-1541 in tumour tissues after an intravenous administration of ODO/HCO-60 emulsions of RS-1541 to mice bearing solid tumour M5076 sarcoma were about ten times higher than those after the administration of SOY/LEC emulsions. These results indicate that HCO-60 emulsions, compared with conventional LEC emulsions, are more stable to lipoprotein lipase and show low uptakes by RES organs, long circulations in the plasma, and high distributions in tumours. Thus, these sterically stabilized emulsions could show potential as effective carriers for highly lipophilic antitumour agents to enhance the drug delivery in tumours.
Kurihara
A
A
Analytical and Metabolic Research Laboratories, Sankyo Co., Ltd., Tokyo, Japan.
Shibayama
Y
Y
Mizota
A
A
Yasuno
A
A
Ikeda
M
M
Sasagawa
K
K
Kobayashi
T
T
Hisaoka
M
M
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004655:Emulsions; D007783:Lactones / Q000008:administration & dosage / Q000493:pharmacokinetics; D008055:Lipids / Q000493:pharmacokinetics; D008066:Lipolysis; D051379:Mice; D008815:Mice, Inbred Strains; D010316:Particle Size; D051381:Rats; D012513:Sarcoma, Experimental / Q000378:metabolism; D014018:Tissue Distribution
D000903:Antibiotics, Antineoplastic; D004655:Emulsions; D007783:Lactones; D008055:Lipids; C087843:palmitoyl rhizoxin